Nuvectis Pharma Inc

Company Profile

Nuvectis Pharma Inc had its IPO on 2022-02-04 under the ticker symbol NVCT.

The company operates in the Healthcare sector and Biotechnology industry. Nuvectis Pharma Inc has a staff strength of 11 employees.

Stock update

Shares of Nuvectis Pharma Inc opened at $13.78 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $13.5 - $14.45, and closed at $14.01.

This is a +2.19% increase from the previous day's closing price.

A total volume of 48,167 shares were traded at the close of the day’s session.

In the last one week, shares of Nuvectis Pharma Inc have slipped by -5.34%.

Nuvectis Pharma Inc's Key Ratios

Nuvectis Pharma Inc has a market cap of $255.02 million, indicating a price to book ratio of 5.3973 and a price to sales ratio of 0.

In the last 12-months Nuvectis Pharma Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Nuvectis Pharma Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Nuvectis Pharma Inc’s operating margin was 0% while its return on assets stood at -68.24% with a return of equity of -140.3%.

In Q2, Nuvectis Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Nuvectis Pharma Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.54 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Nuvectis Pharma Inc’s profitability.

Nuvectis Pharma Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -5.8641. Its price to sales ratio in the trailing 12-months stood at 0.

Nuvectis Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$24.94 million

Total Liabilities

$4.61 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Nuvectis Pharma Inc ended 2024 with $24.94 million in total assets and $0 in total liabilities. Its intangible assets were valued at $24.94 million while shareholder equity stood at $20.33 million.

Nuvectis Pharma Inc ended 2024 with $0 in deferred long-term liabilities, $4.61 million in other current liabilities, in common stock, $-41742000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $24.60 million and cash and short-term investments were $24.60 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Nuvectis Pharma Inc’s total current assets stands at $24.94 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.80 million and inventory worth $0.

In 2024, Nuvectis Pharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Nuvectis Pharma Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$14.01

52-Week High

$18.65

52-Week Low

$6.21

Analyst Target Price

$20.5

Nuvectis Pharma Inc stock is currently trading at $14.01 per share. It touched a 52-week high of $18.65 and a 52-week low of $18.65. Analysts tracking the stock have a 12-month average target price of $20.5.

Its 50-day moving average was $14.64 and 200-day moving average was $12.72 The short ratio stood at 7.38 indicating a short percent outstanding of 0%.

Around 6033.8% of the company’s stock are held by insiders while 1500% are held by institutions.